Mycoplasma pneumoniae Vaccine: Antigenicity of Buffered Antigens in Volunteers
AUTOR(ES)
Brown, Richard C.
RESUMO
The antigenicity of experimental Mycoplasma pneumoniae vaccines prepared from antigen grown in a medium buffered with N-2-hydroxyethylpiperazine-N′-2′-ethanesulfonic acid was tested in young, adult males. Formalin-inactivated antigens from a high-passage strain and a low-passage strain at various dilutions (12 to 123 μg of N/ml) were injected intramuscularly in 1-ml doses. Antibody responses were tested by the metabolic inhibition (MI) technique. Sixty-five to 86% of the volunteers in all vaccine groups responded with fourfold or greater MI antibody rises, but only nine (39%) of 23 antibody-free subjects converted compared to 53 (88%) of 60 of those with pre-existing antibody. A booster vaccination did not increase the number of converters or enhance the geometric mean titers. The antigen concentrations of vaccines with 24 or more μg of N/ml appeared to be above the threshold needed for maximal antibody responses in the dose range tested. MI antibody rises could not be detected in sputa and nasal washings obtained from a small group of vaccinees. The results of this study suggest that the new vaccines offer little or no improvement in antigenicity in man over earlier inactivated vaccines.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=422422Documentos Relacionados
- Expression of Mycoplasma pneumoniae antigens in Escherichia coli.
- Isolation and Characterization of Fractions of Mycoplasma pneumoniae II. Antigenicity and Immunogenicity
- Antibody to Mycoplasma pneumoniae in Nasal Secretions and Sputa of Experimentally Infected Human Volunteers
- Asymptomatic Infection of Adult Volunteers with a Temperature Sensitive Mutant of Mycoplasma pneumoniae
- Haemophilus influenzae vaccine: maximizing uptake.